Organization launches global initiatives, expands patient programs, strengthens policy leadership, and achieves record engagement in 2025
NEW YORK, NY — [January 13, 2026] — In 2025, Ovarian Cancer Research Alliance (OCRA) delivered a year defined by action—launching new global research initiatives, expanding support and education programs, strengthening advocacy and policy leadership, and setting new records for engagement across its community.
Throughout the year, OCRA translated this momentum into measurable progress, including the creation of international research collaborations, record participation in advocacy leadership programs, expanded access to patient-centered support and education, and strengthened policy efforts on behalf of people affected by ovarian and gynecologic cancers.
This year marked a moment of significant forward movement,” said Audra Moran, President and CEO of OCRA. “Across every pillar of our mission—research, support, education, and advocacy—we took meaningful steps to accelerate discovery, broaden access to care, and amplify the voices of patients and families.
Advancing Research and Global Collaboration
In 2025, OCRA invested more than $10.8 million in scientific research, as part of a $14.5 million total organizational commitment across research, patient support, education, and advocacy. This year’s grant cycle drew the highest number of research proposals in the organization’s history, reflecting growing scientific engagement in ovarian and gynecologic cancer research. Updates from newly funded projects will be shared in 2026.
OCRA also launched the Global Ovarian Cancer Research Consortium, a first-of-its-kind international collaboration connecting partners across the United States, Australia, Canada, and the United Kingdom to foster data sharing and coordinated discovery.
In parallel, OCRA continued preparations for the debut of the Community Accelerated Research Exchange (CARE)—a global, AI-powered research ecosystem designed to connect patients, advocates, researchers, and clinicians and enable real-world, patient-driven discovery.
Strengthening the OCRA Family
Two respected organizations joined OCRA in 2025, expanding its mission and reach. The Clearity Foundation, known for its personalized, science-based support services including Steps 1:1 Counseling, and the Rivkin Center for Ovarian Cancer Research, recognized for funding innovative research and signature programs such as the Ovarian Cancer Research Symposium, in conjunction with the American Association for Cancer Research, and SummeRun, are now part of the OCRA family.
Advocacy and Policy Leadership
OCRA took significant steps in 2025 to advance care, access, and support through policy and advocacy. The organization launched its new Center for Public Policy, expanded its policy priorities, and led its strongest Advocacy Day to date—mobilizing a record number of trained volunteer advocates to engage lawmakers at the federal and state levels.
The year also saw a record number of applicants seeking to become OCRA Advocate Leaders, underscoring growing grassroots engagement and increasing demand for informed, patient-centered advocacy. Together, these efforts reinforced the expanding influence of evidence-based advocacy in shaping policy and improving outcomes.
Expanded Support and Education
OCRA expanded its support and education programs in 2025, doubling Steps 1:1 Counseling in size to serve people with all gynecologic cancers. New workshops, webinars, and expert-led roundtables broadened access to timely, evidence-based information for patients, caregivers, and advocates.
Engagement increased across OCRA’s Patient Support Line, Staying Connected Support Series, and Woman to Woman Peer Mentor Program. OCRA’s international online conference—offered free for the first time—achieved its highest attendance to date, welcoming participants from more than 60 countries.
Genetic Testing and Prevention
Through OCRA’s genetic testing program, more than 10,000 individuals to date have qualified for free genetic test kits, helping those with inherited risk factors take informed next steps with their healthcare providers. In 2025, OCRA continued to distribute kits and expand awareness of the importance of genetic testing for ovarian and gynecologic cancers.
Through advocacy and partnerships, including collaboration with BlackDoctor.org, OCRA also spotlighted disparities in genetic testing and care—particularly among Black women, who experience disproportionately high mortality rates from ovarian cancer.
Record Philanthropic Support
OCRA also concluded a record-setting year for philanthropic support, reflecting the commitment of individuals, foundations, and partners who continue to invest in advancing research, strengthening patient services, and sustaining advocacy efforts.
Looking Ahead
As OCRA enters 2026, the organization will deepen global research collaborations, fund new scientific discovery, expand patient support and education programs, and continue advancing policies that improve outcomes for people affected by ovarian and gynecologic cancers worldwide.
About Ovarian Cancer Research Alliance (OCRA)
Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to combating ovarian and all gynecologic cancer. Since its founding in 1994, OCRA has invested $140 million in scientific breakthroughs, and supports 95,000 people annually through its programs, which are free to all participants. As the only dedicated voice for ovarian and gynecologic cancer on Capitol Hill, OCRA has helped to secure $3.8 billion in federal research and education funding. Learn more at ocrahope.org.
